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Impaired Natural Killer Cell Phenotype and Function in
Idiopathic and Heritable Pulmonary Arterial Hypertension
Mark L. Ormiston, PhD; Chiwen Chang, PhD; Lu L. Long, PhD; Elaine Soon, MBBChir; Des Jones, PhD;
Rajiv Machado, PhD; Carmen Treacy, BSc; Mark R. Toshner, MBBS; Kate Campbell, MSc;
Alex Riding, MBBChir; Mark Southwood, PhD; Joanna Pepke-Zaba, PhD, FRCP;
Andrew Exley, MD, FRCPath; Richard C. Trembath, FMedSci; Francesco Colucci, MD, PhD;
Mark Wills, PhD; John Trowsdale, PhD, FMedSci*; Nicholas W. Morrell, MD, FMedSci*
Background—Beyond their role as innate immune effectors, natural killer (NK) cells are emerging as important regulators
of angiogenesis and vascular remodeling. Pulmonary arterial hypertension (PAH) is characterized by severe pulmonary
vascular remodeling and has long been associated with immune dysfunction. Despite this association, a role for NK cells
in disease pathology has not yet been described.
Methods and Results—Analysis of whole blood lymphocytes and isolated NK cells from PAH patients revealed an
expansion of the functionally defective CD56/CD16 NK subset that was not observed in patients with chronic
thromboembolic pulmonary hypertension. NK cells from PAH patients also displayed decreased levels of the activating
receptor NKp46 and the killer immunoglobulin-like receptors 2DL1/S1 and 3DL1, reduced secretion of the cytokine
macrophage inflammatory protein-1, and a significant impairment in cytolytic function associated with decreased killer
immunoglobulin-like receptor 3DL1 expression. Genotyping patients (n222) and controls (n191) for killer
immunoglobulin-like receptor gene polymorphisms did not explain these observations. Rather, we show that NK cells
from PAH patients exhibit increased responsiveness to transforming growth factor-, which specifically downregulates
disease-associated killer immunoglobulin-like receptors. NK cell number and cytotoxicity were similarly decreased in
the monocrotaline rat and chronic hypoxia mouse models of PAH, accompanied by reduced production of interferon-
in NK cells from hypoxic mice. NK cells from PAH patients also produced elevated quantities of matrix
metalloproteinase 9, consistent with a capacity to influence vascular remodeling.
Conclusions—Our work is the first to identify an impairment of NK cells in PAH and suggests a novel and substantive
role for innate immunity in the pathobiology of this disease. (Circulation. 2012;126:1099-1109.)
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Pulmonary arterial hypertension (PAH) is characterized bya loss of pulmonary vasculature at the level of the
precapillary arterioles. This pathological vascular remodeling
is marked by excessive muscularization of the remaining
pulmonary arteries and the formation of obstructive vascular
lesions associated with the aberrant proliferation of endothe-
lial cells, vascular smooth muscle cells, and fibroblasts. The
resulting elevation of pulmonary arterial pressure leads to
right ventricular hypertrophy and death from right heart
failure. Recently, members of the transforming growth
factor- (TGF-) superfamily have been recognized as crit-
ical mediators of pulmonary vascular remodeling. Mutations
in the gene encoding the bone morphogenetic protein type II
receptor account for 70% of heritable PAH cases and 15%
to 40% of cases of the sporadic form of the disease.1 Reduced
bone morphogenetic protein signaling and heightened TGF-
signaling have been reported in pulmonary vascular cells
from PAH patients, whether or not a mutation is present, and
in animal models of disease, as well.2,3
Editorial see p 1020
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Although PAH is primarily considered to be a vascular
disease, there is a well-established link between PAH and
Received September 13, 2011; accepted June 18, 2012.
From the Departments of Medicine (M.L.O., L.L.L., E.S., M.R.T., A.R., M.W., N.W.M.) and Pathology (C.C., D.J., J.T.), Cambridge Institute for
Medical Research; Department of Obstetrics and Gynecology, University of Cambridge, Cambridge (F.C.); Division of Genetics & Molecular Medicine,
King’s College London, London (R.M., R.C.T.); Pulmonary Vascular Diseases Unit (C.T., J.P.-Z.); and Department of Pathology, Papworth Hospital,
Papworth, United Kingdom (K.C., M.S., A.E.).
*Drs Trowsdale and Morrell are joint senior authors.
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.
112.110619/-/DC1.
Correspondence to Nicholas W. Morrell, MD, FMedSci or Mark L. Ormiston, PhD, University of Cambridge, Department of Medicine, Level 5,
Addenbrooke’s Hospital, Box 157, Hills Rd, Cambridge, CB2 0QQ, United Kingdom. E-mail nwm23@cam.ac.uk
© 2012 American Heart Association, Inc.
Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.112.110619
1099 at KINGS COLLEGE LONDON on October 1, 2012http://circ.ahajournals.org/Downloaded from 
immune dysfunction, both in the setting of autoimmune
disease and viral infection. For example, the prevalence of
PAH is 300-fold higher in the HIV patient population
(0.46%) than in the general population.4,5 Despite this link,
there is limited understanding of the precise nature of altered
immunity in PAH and how it might lead to vascular remod-
eling. Many studies have focused on circulating cytokines6 or
elements of the adaptive immune system in animal models of
PAH.7 In comparison, the contribution of innate immunity,
and specifically the potential role of innate lymphocytes such
as natural killer (NK) cells, has received considerably less
attention.
NK cells are best known for their capacity to target and
eliminate stressed, virally infected or oncogene-transformed
cells independent of specific antigen recognition. However, a
growing body of literature supports a role for NK cells in a
wide array of physiological processes, including the regula-
tion of vascular remodeling and regeneration.8–10 Much of
this work has centered on the critical role for decidual NK
(dNK) cells in the remodeling of spiral arteries at the
maternal-fetal interface. During the first trimester of preg-
nancy, the spiral arteries are transformed from narrow, highly
muscularized vessels into amuscular, trophoblast-lined chan-
nels that lack vasomotor responsiveness.11 The importance of
NK cells in this process is supported by studies demonstrating
an association between preeclampsia, a disease of inadequate
spiral artery remodeling, and the interaction of certain mem-
bers of the killer immunoglobulin-like receptor (KIR) family
with their class I major histocompatibility complex (MHC-I)
ligands.12 In PAH, recent work in the monocrotaline rat
model of disease has also implicated a role for NK cells in the
mode of action of experimental, cell-based therapies.13 How-
ever, it is hitherto unknown whether an abnormal NK cell
phenotype exists in patients with idiopathic or heritable PAH.
Natural killer cells also feature in the pathogenesis of HIV,
where several studies have reported an altered NK cell
phenotype and reduced function. HIV-seropositive individu-
als exhibit altered proportions of the CD56bright/CD16 and
CD56dim/CD16 NK cell subsets, related to a rise in circu-
lating levels of functionally deficient, CD56/CD16 NK
cells.14 NK cells from HIV patients also exhibit decreased
surface expression of activating receptors and altered inhib-
itory receptor expression, corresponding to an impaired
capacity to lyse both tumor cell lines and HIV-infected
autologous target cells.14,15
Considering the association between PAH and HIV, we
sought to determine whether similar defects were present in
circulating NK cells from idiopathic and heritable PAH
patients. We performed a phenotypic and functional evalua-
tion of NK cells from PAH patients and demonstrated marked
differences in the absolute levels of circulating NK cell
subsets, decreased surface expression of both activating and
inhibitory receptors, a substantial impairment of functional
capacity, and elevated production of extracellular matrix-
degrading enzymes. This dysfunction does not appear to be
directly linked to genetic predisposition in the patient popu-
lation, but, instead, it may arise from altered TGF- signal-
ing. In the monocrotaline rat and chronic hypoxic mouse
models of PAH, we were able to confirm defects in NK cell




Flow cytometric analysis of whole blood lymphocytes was per-
formed on 11 PAH patients, 9 patients with chronic thromboembolic
pulmonary hypertension (CTEPH), and 37 healthy donors (online-
only Data Supplement Table I). PAH and CTEPH cohorts were
matched for hemodynamic parameters. Analysis of magnetically
isolated NK cells was performed on peripheral blood samples from
14 PAH patients, 4 of whom have identified mutations in the gene
for bone morphogenetic protein type II receptor, and 15 healthy
donors with an equivalent distribution of age, sex, and ethnicity
(online-only Data Supplement Table II). All subjects gave informed
consent to participate in the study, which was approved by the
institutional ethical review committee.
Characterization of Whole Blood Lymphocytes
and Magnetically Isolated NK Cells
Whole blood lymphocytes were analyzed by flow cytometry as
described previously.16 Peripheral blood mononuclear cells were
isolated from whole blood by density gradient centrifugation by
using Ficoll Paque Plus (GE Healthcare, NJ) and enriched for NK
cells by negative magnetic selection using the EasySep NK cell
enrichment kit (StemCell Technologies) according to the manufac-
turers’ instructions. Freshly isolated NK cells were characterized
with the use of the antibodies listed in the online-only Data
Supplement Methods.
Human CD107a Mobilization Assay
NK cells (5104 cells/well) were cultured with or without K562
target cells at a ratio of 1:1 in round-bottom 96-well plates in the
presence of 5 L of PE-Cy5-conjugated -CD107a antibody (clone
H4A3, BD Biosciences, NJ). After 1 hour, 6 g/mL monensin
(GolgiStop, BD Biosciences) was added to each well, and the
cultures were continued for an additional 4 hours. Following cocul-
ture, cells were washed and stained with -CD56-APC, -CD16-
FITC, and -KIR3DL1-PE (all BD Biosciences) or -KIR2DL1/
S1-PE (Beckman Coulter, CA) before analysis.
Human NK Cell Culture and Gene Expression
NK cells (2105 cells/well) were maintained in 0.2 mL RPMI 1640
media with L-glutamine, 10% fetal bovine serum, and 0.5 U/mL
penicillin-streptomycin in round-bottom 96-well plates, with or
without 10 ng/mL of recombinant human TGF- (R&D Systems,
MN) for 72 hours, followed by staining with -CD56-APC,
-CD16-FITC, and PE-conjugated antibodies for KIR3DL1,
KIR2DL1/S1, or KIR2DL2/3 (Beckman Coulter). For gene expres-
sion, RNA was obtained from 6105 NK cells after 24 hours of
culture and purified by using RNeasy RNA isolation columns
(Qiagen, MD). The expression of plasminogen activator inhibitor-1
(PAI-1) and urokinase plasminogen activator (uPA) were determined
relative to the hypoxanthine phosphoribosyltransferase (HPRT) ref-
erence gene by real-time polymerase chain reaction by the use of
Qiagen QuantiTect primer assays.
Statistical Analysis
All data are presented as meanSEM, and a threshold of P0.05
was used for declaring statistical significance. Unpaired, 2-sided
Student t tests were used for comparisons between 2 groups. Paired,
2-sided t tests were used for the analysis of within-person compar-
isons. For the analysis of genotype frequency data, a Bonferroni
correction was used to account for multiple independent comparisons
between 2 groups. Comparisons between multiple groups were
assessed by ANOVA, followed by a Dunnett post hoc analysis.
Statistical analysis was performed by using Prism software (Graph-
Pad Software Inc, CA). We acknowledge that many of the analyses
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in the current study involve the comparison of small group sizes and
that this factor limits our power to detect differences between groups.
For additional methods please see the online-only Data Supple-
ment. All primers used for genotyping studies are listed in online-
only Data Supplement Table III.
Results
Circulating CD56dim/CD16 NK Cells Are
Decreased in PAH Patients
Circulating NK cells can be divided into 2 main subsets,
CD56dim/CD16 cells, which contain all the necessary cellu-
lar machinery for cytotoxicity, and CD56bright/CD16 cells,
which have little to no cytotoxic capacity, but produce large
quantities of inflammatory cytokines on stimulation.17 As an
initial screen, freshly isolated peripheral blood mononuclear
cells were stained for CD56 and CD3 and analyzed by flow
cytometry (Figure 1A through 1C). As previously reported
for HIV, the absolute number of circulating CD56dim/CD3
NK cells was significantly decreased in PAH patients in
comparison with healthy donors (Figure 1B). Samples from
CTEPH patients, hemodynamically matched to the PAH
cohort (online-only Data Supplement Table I), demonstrated
no significant difference in the absolute number of CD56dim/
CD3 cells in comparison with healthy controls. No differ-
ences in the number of circulating CD56bright/CD3 NK cells
were observed between the groups (Figure 1C).
Previous reports have attributed the decrease in CD56dim
NK cells in HIV patients to a rise of CD56/CD16 NK cells
in the circulation, a subset that is linked to impaired NK cell
function.14 Analysis of magnetically isolated NK cells from
PAH patients demonstrated a loss of CD56 on the CD16
population, resulting in a proportional increase in circulating
CD56/CD16 NK cells in comparison with healthy donors
(Figure 1D and 1E).
Analysis of Activating and Inhibitory Receptors on
Isolated NK Cells
The ability of NK cells to lyse potential targets is determined
through the integration of opposing signals from activating
and inhibitory receptors that recognize ligands on the target
cell surface. Magnetically isolated NK cells from PAH
patients and healthy donors were analyzed for a panel of
activating receptors, including DNAM-1, NKG2D, and the
natural cytotoxicity receptors NKp46 and NKp30 (Figure
2A). The surface expression of NKp46 was significantly
decreased on NK cells from PAH patients in comparison with
controls. No significant differences were observed in surface
expression of DNAM-1, NKp30, or NKG2D.
Isolated NK cells were also assessed for surface expression
of activating and inhibitory KIRs (Figure 2B and 2C). NK
cells from PAH patients exhibited a decreased percentage
of cells that bound the EB6B monoclonal antibody, which
recognizes both the inhibitory KIR2DL1 and activating
KIR2DS1 receptors. In contrast, binding of the GL183
antibody, which recognizes the KIR2DL2 and KIR2DL3
inhibitory receptors and the activating KIR2DS2, was ob-
served at similar levels on NK cells from both PAH patients
and healthy donors. Analysis of the inhibitory receptor
Figure 1. Quantification of circulating NK cell subsets. A, Whole blood mononuclear cells, stained for CD56 and CD3 and gated on the
lymphocyte population. Absolute quantification of CD3/CD56dim (B) and CD3/CD56bright (C) NK cells in the circulation of healthy
donors (n37), CTEPH patients (n9) and PAH patients (n11). D, Magnetically-isolated NK cells from healthy donors and PAH
patients, stained for CD56 and CD16. E, Quantification of CD56/CD16 cells as a percentage of total NK cells. n14 to 15; *P0.05.
NK indicates natural killer; CTEPH, chronic thromboembolic pulmonary hypertension; and PAH, pulmonary arterial hypertension.
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KIR3DL1 revealed dramatic decreases in both the percentage
of KIR3DL1 cells and the mean surface expression of this
receptor on NK cells from PAH patients (Figure 2C).
NK Cells From PAH Patients Are
Functionally Impaired
Recent reports have implicated a role for inhibitory, MHC-
I–binding receptors, including members of the KIR family, in
the education of NK cells and the enhancement of their
killing capacity.18 Having demonstrated decreased expression
of certain KIRs in association with PAH, NK cell function
was assessed by measuring degranulation via -CD107a
antibody uptake in the presence or absence of the MHC-I–
deficient, K562 target cell line (Figure 3A). Analysis of total
CD107a NK cells demonstrated a significant decrease in the
overall functional capacity of circulating NK cells from PAH
patients in comparison with healthy donors (Figure 3B).
Staining of NK cells for KIR3DL1 or KIR2DL1/S1 after
coculture allowed for a determination of the contribution of
these KIR subsets to the total lytic response of the entire NK
cell population. To control for differences in MHC-I type
between individuals, all subjects were genotyped and only
those expressing the appropriate human leukocyte antigen
(HLA) ligand for each KIR (HLA-Bw4 for KIR3DL1 and
HLA-C2 for KIR2DL1/S1) were included in subsequent
analyses. Division of CD107a positivity into relative contri-
butions from the KIR3DL1-positive and -negative popula-
tions demonstrated that, in healthy individuals expressing the
HLA-Bw4 ligand, expression of the inhibitory KIR3DL1 on
a particular NK cell results in an increased propensity of that
cell to degranulate when cultured with target cells (Figure
3C). In HLA-Bw4 PAH patients, expression of KIR3DL1
provided no such enhancement of functional capacity, sug-
gesting that decreased KIR3DL1 expression is responsible for
at least part of the impaired functional capacity of NK cells
in these individuals. In the case of KIR2DL1 and 2DS1,
expression of at least one of these receptors, as indicated
by binding of the EB6B antibody, did not result in
enhanced lytic activity in either group (Figure 3D). How-
ever, this result may be attributable to the lack of speci-
ficity of the EB6B antibody.
Cytokine secretion in response to K562 cell stimulation, as
measured by macrophage inflammatory protein-1 produc-
tion, was also significantly decreased in NK cells from PAH
patients in comparison with cells from healthy donors (Figure
3E), further confirming the functional impairment of these
cells in PAH. Parallel cultures containing NK or K562 cells
alone resulted in baseline macrophage inflammatory
protein-1 production that was below the detectable thresh-
old of the assay (data not shown).
For PAH patients, no correlation was observed between
NK cell dysfunction and disease severity, as determined by
hemodynamic parameters or 6-minute walk distance (data not
shown).
Figure 2. Analysis of NK surface receptor expression. Flow cytometric analysis of activating receptors (A) and KIRs (B) on magnetically
isolated NK cells. Receptor expression quantified as shift in mean fluorescence intensity versus isotype (gray) (A) or percentage of posi-
tive NK cells (B). C, Percentage of positivity and mean fluorescence intensity of KIR3DL1 on magnetically isolated NK cells from PAH
patients (red) and healthy donors (green). n11 to 15 per group; *P0.05. NK indicates natural killer; PAH, pulmonary arterial
hypertension.
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Decreased KIR Levels Are Not Associated With
KIR or HLA Gene Polymorphisms
The KIR family of genes displays a high level of diversity at
the allelic level, and extensive locus-specific polymorphic
variability, as well. In the case of KIR3DL1, different
polymorphic forms of the 3DL1 gene have been shown to
result in distinct levels of NK cell surface expression. The
most common of these polymorphisms have been categorized
into forms that result in high (*001, *002, *0152, *020), low
(*005, *007), and no (*004) surface expression.19,20 In
addition to the many polymorphic forms of the inhibitory
receptor, the 3DL1 locus can also encode an activating
receptor, KIR3DS1.
To address the possibility that the decreased KIR3DL1
levels observed in our PAH patients were the result of a
genetic predisposition in this group, a cohort of 222 British
white PAH patients and 191 ethnicity-matched control sub-
jects was typed for the KIR3DL1 and 3DS1 forms of the
3DL1 locus (Figure 4A). KIR3DL1-positive individuals were
also typed for 7 of the most common polymorphic variants of
KIR3DL1 (Figure 4B). This analysis failed to reveal any
significant differences in the frequency of KIR3DL1, 3DS1,
or any of the KIR3DL1 polymorphisms in PAH patients in
comparison with controls.
The complex regulation of KIR surface expression is
further compounded by the influence of HLA ligands, which
can induce clonal expansion of NK cells expressing comple-
mentary KIR molecules and are themselves highly variable.
The ligands for KIR3DL1 are HLA-B molecules and a few
HLA-A types that contain the Bw4 motif.21,22 Bw4 allo-
types containing isoleucine at position 80 (Bw480I) are
preferential ligands over types with threonine at this
position (Bw480T).23,24 KIR2DL1 and KIR2DS1 receptors
bind the C2 form of the HLA-C molecule, whereas C1
allotypes are ligands for KIR2DL3 and weakly bind
2DL2.25 The PAH and control cohorts were also genotyped
for HLA-Bw6, HLA-Bw4 – 80T, and Bw4 – 80I (Figure
4C), and HLA-C1 and C2 (Figure 4D), as well. Again, no
significant differences in allelic frequencies were found
between the groups. Taken together, these results suggest
that the observed differences in KIR surface expression on
NK cells from PAH patients are not the direct result of a
genetic predisposition, but may instead result from in vivo
conditioning.
Figure 3. Functional analysis of circulating NK cells. A, Representative flow plots gated on CD16 NK cells following incubation with or
without K562 target cells (1:1) in the presence of -CD107a MAb. B, Quantification of total CD107a NK cells from all subjects (n12–
14) after coculture with K562 cells. C and D, Quantification of CD107a positivity in NK cells subdivided for expression of KIR3DL1 (C)
and KIR2DL1/S1 (D). Significance determined by paired t test comparing KIR-positive and -negative subsets from the same individual.
Only individuals expressing both the KIR of interest and the appropriate HLA ligand for each KIR were assessed. E, Quantification of
MIP-1 secretion by isolated NK cells (n12–14) incubated with K562 target cells. *P0.05. NK indicates natural killer; MAb, monoclo-
nal antibody; PAH, pulmonary arterial hypertension; HLA, human leukocyte antigen; KIR, killer immunoglobulin-like receptor; and MIP-
1, macrophage inflammatory protein-1.
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TGF- Regulates KIR Surface Expression
Considering the central role for the TGF- superfamily in the
pathogenesis of PAH, we questioned whether the impaired
NK phenotype in PAH could be attributed to altered TGF-
signaling in these individuals. Treatment of freshly isolated
NK cells from healthy donors with 10 ng/mL TGF- induced
a substantial drop in the surface expression of KIR3DL1 and
KIR2DL1/S1, the 2 markers that were decreased in PAH
(Figure 5A). In contrast, surface levels of KIR2DL2/3, which
was unaltered in PAH patients, was relatively insensitive to
TGF- stimulation. A comparison of changes in KIR surface
expression did not show greater reductions in KIRs following
TGF- stimulation in the patient group in comparison with
controls (data not shown). However, this was likely due to the
Figure 4. Genotype frequencies of KIR3DL1,
KIR3DS1, HLA-B, and HLA-C variants in PAH
and control cohorts. A, A cohort of British,
white healthy controls (, n191) and PAH
patients (f, n222) were genotyped for allelic
frequency of KIR3DL1 and 3DS1, and poly-
morphic variants of KIR3DL1 (B), as well. All
subjects were also typed for variants of HLA-B
(C) and HLA-C (D). Significance was deter-
mined by the Fisher exact test (*P0.05), with
a Bonferroni correction for comparisons of
3DL1 subtype frequency. No significant differ-
ences were found between the groups. PAH
indicates pulmonary arterial hypertension.
Figure 5. Response of isolated NK cells to TGF- stimulation. A, Representative plots of magnetically isolated NK cells from a healthy
donor cultured for 72 hours with or without 10 ng/mL TGF-. B, After 72 hours ex vivo, NK cells from a subset of PAH patients exhib-
ited a recovery in KIR3DL1 expression that was blocked by the addition of TGF-. Gene expression of PAI-1 (C) and uPA (D) in NK
cells after 24 hours of ex vivo culture with or without TGF- stimulation. n12 to 14; *P0.05. NK indicates natural killer; PAH, pulmo-
nary arterial hypertension; TGF-, transforming growth factor-; HPRT, hypoxanthine phosphoribosyltransferase; PAI-1, plasminogen
activator inhibitor-1; and uPA, urokinase plasminogen activator.
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fact that NK cells from patients already exhibited depressed
KIR expression at the time of isolation. In support of this, NK
cells from PAH patients exhibited a marked recovery in
KIR3DL1 levels after 72 hours ex vivo (Figure 5B). This
recovery, which was not observed for any healthy control
subjects or for KIR2DL1/S1 expression in either patients or
controls, was blocked if TGF- was added to the culture
medium.
Gene expression of PAI-1 and uPA were used as down-
stream measures of TGF- signaling in cultured NK cells.
Cells from PAH patients demonstrated increased baseline
expression of PAI-1 and uPA. A greater increase in PAI-1
gene expression was also observed in NK cells from PAH
patients versus controls following stimulation with TGF-
(Figure 5C). No such effect was observed with uPA, for
which gene expression was likely maximal in both groups
following TGF- stimulation. Together, these findings sug-
gest that the impaired NK cell phenotype observed in PAH is
the result of excessive TGF- signaling. In agreement with
previous reports investigating TGF- signaling in pulmonary
vascular smooth muscle cells from PAH patients,3 division of
the PAH cohort based on the presence or absence of a
mutation in the gene for bone morphogenetic protein type II
receptor revealed similarly increased of TGF- signaling in
both groups (online-only Data Supplement Figure I).
Decreased NK Cell Number and Function in
Rodent Models of PAH
To determine the relevance of these findings in vivo, we
examined NK cell function in both the monocrotaline rat
model and chronic hypoxic mouse model of PAH. Rats given
monocrotaline developed pulmonary hypertension by 21 days
after injection, as evidenced by elevated right ventricular
systolic pressures and right ventricular hypertrophy (Figure
6A and 6B). In agreement with previous findings in the rat
model,2 monocrotaline-induced pulmonary hypertension
Figure 6. NK cell number and function are decreased in monocrotaline-induced pulmonary hypertension. Right ventricular systolic
pressure (A) and right ventricular hypertrophy (B) 21 days after intraperitoneal injection of MCT or an equivalent volume of saline. Gene
expression of PAI-1 (C) and kir3dl1 (D) in the lungs of rats treated with monocrotaline or saline control. E, Representative flow plots of
peripheral blood and splenic lymphocytes, isolated from (MCT)-challenged or control rats and stained for CD3 and NKR-P1A. F, Quan-
tification of NKR-P1A/CD3 NK cells in the blood and spleen of rats treated with MCT or saline control. G, Functional assessment of
NK cells isolated from MCT- or saline-treated rats. Percentage of lysis of YAC-1 target cells was determined by 51Cr release following
6-hour coculture at an effector-to-target ratio of 80:1. n6; *P0.05. NK indicates natural killer; PAH, pulmonary arterial hypertension;
MCT, monocrotaline; RVSP, right ventricular systolic pressure; RV, right ventricle; LV, left ventricle; S, septum; and PAI-1, plasminogen
activator inhibitor-1.
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was associated with increased TGF- signaling, as dem-
onstrated by increased PAI-1 gene expression in the lungs
of monocrotaline-challenged rats (Figure 6C). Consistent
with findings in human NK cell cultures, increased PAI-1
gene expression was accompanied by significantly decreased
expression of rat kir3dl1 (Figure 6D). Analysis of peripheral
blood and splenic lymphocytes demonstrated decreased num-
bers of NKR-P1A/CD3 NK cells in both tissues for
monocrotaline-treated animals (Figure 6E and 6F). In addi-
tion, splenic NK cells isolated from monocrotaline-
challenged rats were functionally impaired, as demonstrated
by a decreased capacity to lyse the YAC-1 murine lymphoma
target cell line (Figure 6G and online-only Data Supplement
Figure II).
Mice with chronic hypoxia-induced pulmonary hyperten-
sion also exhibited NK cell impairment. Mice maintained at
10% O2 for 21 days developed significantly elevated right
ventricular systolic pressures (Figure 7A) and right ventric-
ular hypertrophy (Figure 7B), associated with increased
pulmonary arteriolar muscularization (Figure 7C through 7E).
Pulmonary hypertension was accompanied by decreased
numbers of NKR-1.1/CD3 NK cells in the blood, spleen,
and lungs of mice maintained under hypoxia (Figure 7F and
7G), and diminished NK cell function in response to stimu-
lation with YAC-1 cells or interleukin 12, as well (Figure
7H). NK cells from hypoxia-exposed mice exhibited de-
creased degranulation in response to both stimuli, as mea-
sured by the CD107a mobilization assay (Figure 7I). As in
humans, naïve murine NK cells have a limited ability to
produce interferon- when cocultured with YAC-1 target
cells. However, stimulation of NK cells with interleukin 12
revealed a decreased capacity of NK cells from hypoxic mice
to secrete interferon-, further highlighting the reduced func-
tional capacity of these cells (Figure 7J).
Increased Matrix Metalloproteinase Production in
NK Cells From PAH Patients
Previous studies examining the mechanism by which dNK
cells influence spiral artery remodeling in pregnancy sug-
gested a role for matrix metalloproteinases (MMPs) in this
process.11,26 Examination of MMP gene expression in ex vivo
NK cell cultures revealed no significant difference in MMP-2
gene expression in PAH NK cells, but did show a significant
increase in the expression of MMP-9 when compared with
healthy donors (Figure 8A and 8B). Quantification of active
enzyme secretion in NK cell culture supernatants by gelatin
zymography revealed no significant increase in active
MMP-2, but did demonstrate increased levels of active
MMP-9 in supernatants from PAH NK cell cultures (Figure
8C). High-molecular-weight forms of MMP-9 were also
observed in 8 of the 12 patient samples, but none of the
control samples. These high-molecular-weight bands have
previously been identified as a complex of MMP-9 with
neutrophil gelatinase-associated lipocalin, which has been
Figure 7. NK cell number and function are decreased in mice exposed to chronic hypoxia. Right ventricular systolic pressure (A) and
right ventricular hypertrophy (B) after 21 days of exposure to hypoxia (10% O2) or normoxia. Lung sections from normoxic (C) and
hypoxic mice (D) stained for von Willebrand factor (green) smooth muscle -actin (red) and DAPI nuclear counterstain (blue). E, Quanti-
tative assessment of pulmonary arterial muscularization, divided into non-, partially, and fully muscularized arteries (n6). F, Represen-
tative flow plots of peripheral blood, splenic and lung lymphocytes from hypoxic and normoxic mice stained for CD45, CD3, and
NK1.1. G, NK1.1/CD3 NK cells in the blood, spleen, and lung were quantified as a percentage of CD45 lymphocytes (n5–8). H
through J, Functional assessment of NK cells from normoxic and hypoxic mice, determined by -CD107a binding (I) and intracellular
IFN production (J) as a percentage of total NK cells (n3–5). *P0.05. NK indicates natural killer; DAPI, 4,6-diamidino-2-
phenylindole;RVSP, right ventricular systolic pressure; RV, right ventricle; LV, left ventricle; S, septum; vWF, von Willebrand factor;
SMA, smooth muscle -actin; IL-12, interleukin 12; and IFN, interferon-.
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shown to preserve MMP-9 activity by protecting the enzyme
from degradation.27 Further examination of extracellular ma-
trix metalloproteinase inducer and tissue inhibitors of MMP
(TIMP-1 and -3) gene expression revealed no significant
differences between patients and controls (online-only Data
Supplement Figure III). However, a significant increase in
TIMP-2 gene expression was observed in NK cells from PAH
patients.
Discussion
Our findings identify for the first time an impairment of NK
cell phenotype and function in human idiopathic and heritable
PAH and 2 widely used animal models of the disease. In
patients, this abnormal NK cell phenotype was marked by a
rise in the functionally deficient CD56/CD16 subset. This
change was not detected in a disease control group of CTEPH
patients, suggesting that the observed NK dysfunction is
specific to PAH and is not a secondary effect of altered
pulmonary hemodynamics.
Beyond altered circulating subsets, NK cells from PAH
patients also exhibited decreased surface levels of activating
and inhibitory receptors, including a decrease in KIR3DL1
that we directly linked to impaired NK cytolytic function in
these individuals. The observation of decreased KIR levels on
NK cells from PAH patients differs from previous findings in
HIV patients, in whom the functional deficiency of circulat-
ing NK cells was attributed to decreased levels of activating
receptors and increased expression of inhibitory KIRs.14
However, our findings are in agreement with a more recent
model of NK cell education.18 Under this model, increased
expression of inhibitory receptors in the presence of the
appropriate MHC-I ligand induces a dependence on inhibi-
tory receptor-ligand interactions to maintain a resting state,
accompanied by more robust cytotoxic responses when that
inhibition is lacking, such as when an NK cell encounters an
MHC-I–deficient target.
Previous studies investigating the role of KIRs in disease
pathogenesis have primarily focused on the capacity of KIR
and HLA gene polymorphism to influence receptor levels and
alter NK cell function. Disease association studies have
shown that KIR-HLA genotype interactions can influence the
outcome of viral infections, including HIV.28 Certain combi-
nations of maternal KIR2D receptors and fetal HLA-C genes
can also influence the risk of preeclampsia and dictate
reproductive success.12 In comparison, relatively little atten-
tion has been given to the possible role of in vivo condition-
ing in the regulation of KIR levels. Here we show that
signaling through the TGF- pathway, known to be perturbed
in PAH, specifically downregulates disease-associated KIRs
in vitro and contributes to the abnormal NK cell phenotype in
patients. Previous studies in pulmonary arterial smooth mus-
cle cells from PAH patients, with and without BMPR-II
mutations, have highlighted altered responses to TGF-
stimulation.3 In agreement with our current findings, in-
creased TGF- signaling has also been reported in the
monocrotaline rat model of PAH, where it was specifically
linked to increased TGF- production by pulmonary artery
smooth muscle cells and macrophages surrounding remod-
eled pulmonary arteries.2 Inhibition of the type I TGF-
receptor, activin-like kinase 5, in this model attenuates and
reverses the disease. In the context of NK cell function,
TGF- is has been shown to decrease surface expression of
the activating receptors NKp30 and NKG2D and reduce
cytotoxic activity.29 There are also limited reports of the
capacity of TGF- to alter KIR expression on cultured NK
cells.30 However, our study is the first to demonstrate a role
for TGF- in the regulation of KIR expression in the context
of a human disease.
As in PAH patients, our findings in the monocrotaline rat
and chronic hypoxic mouse models of PAH demonstrate
similar reductions in NK cell number, cytolytic activity, and
cytokine production. These observations support a role for
NK dysfunction in the pathogenesis of PAH and help address
the limitation of examining NK cells from patients that are at
Figure 8. NK cells from PAH patients exhibit elevated MMP-9
production. Gene expression of MMP-2 (A) and MMP-9 (B) in
isolated NK cells after 24 hours of ex vivo culture. C, Active
MMP-2 (62 kDa), MMP-9 (92 kDa), and MMP-9/NGAL com-
plexes (125 kDa) in supernatant from NK cell cultures, as mea-
sured by gelatin zymography. Quantification of active MMP-2
(D) and MMP-9 (E) secretion by densitometry. n12 to 14;
*P0.05. NK indicates natural killer; PAH, pulmonary arterial
hypertension; HPRT, hypoxanthine phosphoribosyltransferase;
NGAL, neutrophil gelatinase-associated lipocalin; MMP-2, matrix
metalloproteinase 2; and MMP-9, matrix metalloproteinase 9.
Ormiston et al Impaired Natural Killer Cells in PAH 1107
 at KINGS COLLEGE LONDON on October 1, 2012http://circ.ahajournals.org/Downloaded from 
different stages in disease progression and are receiving
treatment with a range of therapies. In addition to reduced NK
cell number and function, increased PAI-1 gene expression
was also observed in the lungs of monocrotaline-challenged
rats, consistent with increased TGF- signaling. This in-
creased PAI-1 expression was accompanied by decreased
transcription of kir3dl1, the only KIR-like sequence that has
been identified in the rat genome.31 Despite the limited and
ambiguous nature of the KIR repertoire in rodents, further
support for a role of KIR3DL1 in PAH was provided by a
recent study identifying kir3dl1 as one of a small number of
genes that is significantly downregulated in the peripheral
blood mononuclear cells of cattle that develop pulmonary
hypertension at high altitude.32
Having demonstrated an impairment of NK cell function in
both human PAH and animal models of disease, the question
remains as to how NK cell dysfunction may contribute to
pathological vascular remodeling. During pregnancy, the
extensive demuscularization of spiral arteries, coupled by a
loss of the endothelial monolayer, represents a precise rever-
sal of the vascular remodeling observed in the PAH lung.
While the role of dNK cells in this process is now commonly
accepted, the mechanism by which this remodeling is
achieved remains uncertain. A recent report by Hanna and
colleagues8 suggested that secreted factors, including dNK-
derived angiogenic factors and chemokines, induce vascular
remodeling and trophoblast migration. Other work using
human tissues has implicated a role for dNK cell-derived
MMPs in the induction of vascular cell apoptosis and the
demuscularization of spiral arteries.11,26 Although dNK cells
are thought to be a distinct subset to circulating NK cell
populations, with a unique capacity to influence vascular
structure, circulating NK cells have also been implicated in
the support of collateral artery formation in a murine model of
hindlimb ischemia9 and in cardiac angiogenesis following
myocardial infarction.10
Our finding of increased MMP-9 gene expression and
enzymatic activity in circulating NK cells from PAH patients
provides a potential mechanism by which these cells can
directly influence pathological pulmonary vascular remodel-
ing. This finding is supported by previous work reporting
elevated MMP-2 and MMP-9 in the lungs of rats with
monocrotaline-induced pulmonary hypertension.33 In addi-
tion to being a surrogate measure for enhanced TGF-
signaling, the identification of increased urokinase gene
expression in NK cells from PAH patients also supports a role
for these cells in the turnover of the extracellular matrix. In
the monocrotaline rat model, it was suggested that MMPs
allow for increased smooth muscle cell motility and the
muscularization of the pulmonary arteries, as has been
described previously for MMPs in the enhancement of tumor
invasion and metastasis.33 However, in pregnancy, MMP
production is associated with the demuscularization of arter-
ies and smooth muscle cell apoptosis,11 suggesting that
increased MMP production in NK cells from PAH patients
may be a protective response to increased pulmonary vascular
muscularization in the diseased lung.
Taken together, this study proposes a potentially important
role for NK cells in the regulation of vascular remodeling
beyond the context of pregnancy and provides novel insights
into the complex mechanisms underlying PAH.
Acknowledgments
The authors thank Dr M. Weale, X. Yang, and Dr P. Jurasz for
assistance with statistical analyses, animal studies, and zymography,
respectively. Dr P. Stevenson provided YAC-1 cells.
Sources of Funding
This work was funded by the British Heart Foundation, Canadian
Institutes of Health Research and Fondation Leducq. Dr Trowsdale is
supported by the Wellcome Trust and MRC. Dr Colucci is supported
by the Wellcome Trust, MRC, and AICR. Research infrastructure




1. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC,
Gruenig E, Janssen B, Koehler R, Seeger W, Eickelberg O, Olschewski
H, Elliott CG, Glissmeyer E, Carlquist J, Kim M, Torbicki A,
Fijalkowska A, Szewczyk G, Parma J, Abramowicz MJ, Galie N,
Morisaki H, Kyotani S, Nakanishi N, Morisaki T, Humbert M,
Simonneau G, Sitbon O, Soubrier F, Coulet F, Morrell NW, Trembath
RC. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary
arterial hypertension. Hum Mutat. 2006;27:121–132.
2. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell
NW. Altered bone morphogenetic protein and transforming growth
factor-beta signaling in rat models of pulmonary hypertension: potential
for activin receptor-like kinase-5 inhibition in prevention and progression
of disease. Circulation. 2009;119:566–576.
3. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK,
Trembath RC. Altered growth responses of pulmonary artery smooth
muscle cells from patients with primary pulmonary hypertension to trans-
forming growth factor-beta(1) and bone morphogenetic proteins. Circu-
lation. 2001;104:790–795.
4. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere
D, Gressin V, Clerson P, Sereni D, Simonneau G. Prevalence of HIV-
related pulmonary arterial hypertension in the current antiretroviral
therapy era. Am J Respir Crit Care Med. 2008;177:108–113.
5. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V,
Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C,
Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G.
Pulmonary arterial hypertension in France: results from a national
registry. Am J Respir Crit Care Med. 2006;173:1023–1030.
6. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado
RD, Trembath RC, Jennings S, Barker L, Nicklin P, Walker C, Budd DC,
Pepke-Zaba J, Morrell NW. Elevated levels of inflammatory cytokines
predict survival in idiopathic and familial pulmonary arterial hyper-
tension. Circulation. 2010;122:920–927.
7. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R,
Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF. Absence
of T cells confers increased pulmonary arterial hypertension and vascular
remodeling. Am J Respir Crit Care Med. 2007;175:1280–1289.
8. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C,
Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit
R, Yutkin V, Benharroch D, Porgador A, Keshet E, Yagel S, Mandelboim
O. Decidual NK cells regulate key developmental processes at the human
fetal-maternal interface. Nat Med. 2006;12:1065–1074.
9. van Weel V, Toes RE, Seghers L, Deckers MM, de Vries MR, Eilers PH,
Sipkens J, Schepers A, Eefting D, van Hinsbergh VW, van Bockel JH,
Quax PH. Natural killer cells and CD4 T-cells modulate collateral
artery development. Arterioscler Thromb Vasc Biol. 2007;27:2310–2318.
10. Bouchentouf M, Forner KA, Cuerquis J, Michaud V, Zheng J, Paradis P,
Schiffrin EL, Galipeau J. Induction of cardiac angiogenesis requires killer
cell lectin-like receptor 1 and 47 integrin expression by NK cells.
J Immunol. 2010;185:7014–7025.
11. Smith SD, Dunk CE, Aplin JD, Harris LK, Jones RL. Evidence for
immune cell involvement in decidual spiral arteriole remodeling in early
human pregnancy. Am J Pathol. 2009;174:1959–1971.
1108 Circulation August 28, 2012
 at KINGS COLLEGE LONDON on October 1, 2012http://circ.ahajournals.org/Downloaded from 
12. Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, Claas
FH, Walker JJ, Redman CW, Morgan L, Tower C, Regan L, Moore GE,
Carrington M, Moffett A. Maternal activating KIRs protect against
human reproductive failure mediated by fetal HLA-C2. J Clin Invest.
2010;120:4102–4110.
13. Ormiston ML, Deng Y, Stewart DJ, Courtman DW. Innate immunity in
the therapeutic actions of endothelial progenitor cells in pulmonary
hypertension. Am J Respir Cell Mol Biol. 2010;43:546–554.
14. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, Planta MA,
Marcenaro E, Bottino C, Moretta L, Moretta A, Fauci AS. Natural killer
cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and
activating receptors and their functional correlates. Proc Natl Acad Sci
U S A. 2003;100:15011–15016.
15. Bonaparte MI, Barker E. Inability of natural killer cells to destroy
autologous HIV-infected T lymphocytes. AIDS. 2003;17:487–494.
16. Exley AR, Buckenham S, Hodges E, Hallam R, Byrd P, Last J, Trinder
C, Harris S, Screaton N, Williams AP, Taylor AM, Shneerson JM.
Premature ageing of the immune system underlies immunodeficiency in
ataxia telangiectasia. Clin Immunol. 2011;140:26–36.
17. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural
killer-cell subsets. Trends Immunol. 2001;22:633–640.
18. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V,
Frassati C, Reviron D, Middleton D, Romagne F, Ugolini S, Vivier E.
Human NK cell education by inhibitory receptors for MHC class I.
Immunity. 2006;25:331–342.
19. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH,
Rajalingam R, Vilches C, Parham P. Different NK cell surface pheno-
types defined by the DX9 antibody are due to KIR3DL1 gene poly-
morphism. J Immunol. 2001;166:2992–3001.
20. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P.
Roles for HLA and KIR polymorphisms in natural killer cell repertoire
selection and modulation of effector function. J Exp Med. 2006;203:
633–645.
21. Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar
AM, Gleimer M, Hammond JA, Guethlein LA, Bushnell DA, Robinson
PJ, Parham P. KIR2DS4 is a product of gene conversion with KIR3DL2
that introduced specificity for HLA-A*11 while diminishing avidity for
HLA-C. J Exp Med. 2009;206:2557–2572.
22. Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A. Human leukocyte
antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1.
Blood. 2008;112:708–710.
23. Gumperz JE, Barber LD, Valiante NM, Percival L, Phillips JH, Lanier
LL, Parham P. Conserved and variable residues within the Bw4 motif of
HLA-B make separable contributions to recognition by the NKB1 killer
cell-inhibitory receptor. J Immunol. 1997;158:5237–5241.
24. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific
natural killer cells are selectively inhibited by Bw4-positive HLA alleles
with isoleucine 80. J Exp Med. 1994;180:1235–1242.
25. Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO. Killer
cell inhibitory receptors specific for HLA-C and HLA-B identified by
direct binding and by functional transfer. Immunity. 1995;3:801–809.
26. Naruse K, Lash GE, Innes BA, Otun HA, Searle RF, Robson SC, Bulmer
JN. Localization of matrix metalloproteinase (MMP)-2, MMP-9 and
tissue inhibitors for MMPs (TIMPs) in uterine natural killer cells in early
human pregnancy. Hum Reprod. 2009;24:553–561.
27. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight
urinary matrix metalloproteinase (MMP) activity is a complex of gela-
tinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL).
Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001;276:
37258–37265.
28. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S,
Brown EE, Shupert WL, Phair J, Goedert JJ, Buchbinder S, Kirk GD,
Telenti A, Connors M, O’Brien SJ, Walker BD, Parham P, Deeks SG,
McVicar DW, Carrington M. Innate partnership of HLA-B and KIR3DL1
subtypes against HIV-1. Nat Genet. 2007;39:733–740.
29. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte
R, Biassoni R, Bottino C, Moretta L, Moretta A. Transforming growth
factor beta 1 inhibits expression of NKp30 and NKG2D receptors: con-
sequences for the NK-mediated killing of dendritic cells. Proc Natl Acad
Sci U S A. 2003;100:4120–4125.
30. Shin EC, Choi KS, Kim SJ, Shin JS. Modulation of the surface expression
of CD158 killer cell Ig-like receptor by interleukin-2 and transforming
growth factor-beta. Yonsei Med J. 2004;45:510–514.
31. Hoelsbrekken SE, Nylenna O, Saether PC, Slettedal IO, Ryan JC, Fossum
S, Dissen E. Cutting edge: molecular cloning of a killer cell Ig-like
receptor in the mouse and rat. J Immunol. 2003;170:2259–2263.
32. Newman JH, Holt TN, Hedges LK, Womak B, Memon SS, Willers ED,
Wheeler L, Phillips JA, Hamid R. High-altitude pulmonary hypertension
in cattle (brisket disease): candidate genes and gene expression profiling
of peripheral blood mononuclear cells. Pulm Circ. 2011;1:462–469.
33. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M,
Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of
experimental pulmonary hypertension by PDGF inhibition. J Clin Invest.
2005;115:2811–2821.
CLINICAL PERSPECTIVE
Pulmonary arterial hypertension (PAH) is a disease of occlusive vascular remodeling that leads to elevated pulmonary
arterial pressure and death from right heart failure. An association between PAH and immune dysfunction has been
recognized for decades, although the cellular basis for this link has remained obscure. In the current study, we identify a
defect in the circulating natural killer (NK) cells of PAH patients and 2 widely used animal models of disease. Beyond their
traditional function as the cytotoxic effector cells of innate immunity, several studies have recently demonstrated a role for
NK cells in the regulation of spiral artery remodeling during pregnancy, tumor angiogenesis and the revascularization of
ischemic limbs. By drawing upon recent literature characterizing the impairment of NK cells in HIV infection, we identify
an altered NK cell phenotype in PAH patients that is exemplified by decreased surface expression of certain killer
immunoglobulin-like receptors, diminished cytotoxicity, reduced cytokine secretion, and the increased production of
matrix-degrading enzymes, including matrix metalloproteinase 9. We also propose a mechanism whereby this NK cell
impairment is the result of excessive transforming growth factor- signaling. Our work is the first to propose a direct role
for NK cells in the regulation of pulmonary vascular remodeling. This discovery, which is based on emerging concepts
from reproductive medicine and immunology, not only highlights the importance of cellular immunity in the pathobiology
of PAH, but also provides a potential therapeutic target for the design of new PAH treatments.
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SUPPLEMENTAL MATERIAL 
Supplemental Methods 
Characterization of magnetically isolated NK cells 
The surface receptor expression of magnetically isolated NK cells was characterized by 
staining with the following primary antibodies α-CD56-APC (clone B159), α -CD16-
FITC (clone 3G8), α -KIR3DL1-FITC (clone DX9), α-KIR2DL2/3-FITC (clone GL183), 
α-NKG2D (clone 1D11), α-DNAM1 (clone DX11, all from BD Biosciences, Franklin 
Lakes, NJ), α-KIR2DL1/S1-FITC (clone EB6B, Beckman Coulter, Brea, CA), α-NKp46 
(clone 9E2, Miltenyi Biotec, Gladbach, Germany), α-NKp30 (clone AF29-4D12, 
Miltenyi Biotec) and mouse IgG1k isotype control (BD Biosciences).  Unconjugated 
primary antibodies were used in conjunction with a goat-a-mouse IgG-APC secondary 
(R&D Systems, Minneapolis, MN).  For CD56/CD16 dual staining, enriched NK cells 
were fixed and residual red blood cells were lysed after staining using BD Biosciences 
FACS lysis solution.  All other samples were analyzed fresh. 
Human NK cell cytokine secretion 
For the measurement of NK cell cytokine secretion, parallel cultures were conducted as 
described for the CD107a mobilization assay without the addition of monensin or α-
CD107a antibody. After 5 hours, supernatants were collected and macrophage 
inflammatory protein-1β (MIP-1β) secretion was quantified using a DuoSet ELISA kit 
(R&D Systems) as per manufacturer’s instructions.  
KIR and HLA genotyping 
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As described previously1, genomic DNA samples, isolated from British, Caucasian PAH 
patients (n=222) or ethnically-matched blood donors (n=191) were genotyped for 
KIR3DL1, KIR3DS1, HLA-B and HLA-C using the sequence specific primers in 
Supplemental Table III. Samples were also typed for common polymorphisms of 3DL1, 
as reported by Yawata and colleagues2. Of the 222 samples in the PAH cohort, 13 
possessed mutations in the gene for BMPR-II. 
Rodent models of pulmonary hypertension 
Male Sprague-Dawley rats, weighing 350-425 grams (Charles River, Margate, UK) were 
randomized and given intraperitoneal injections of either monocrotaline (60mg/kg, Sigma 
Aldrich, Saint Louis, MO) or an equivalent volume of sterile saline. On day 21, rats were 
anaesthetized with fentanyl, fluanisone and midazolam and right ventricular systolic 
pressure (RVSP) was measured by a 1.4F Millar catheter (Millar Instruments, Houston, 
TX). Blood was collected from the abdominal aorta. Following sacrifice, spleens, hearts 
and lung tissue were harvested and right ventricular (RV) hypertrophy was measured as a 
ratio of RV to left ventricular and septal weight (RV/L+S). RNA was isolated from snap 
frozen lung tissue by trizol extraction. Gene expression levels of PAI-1 and kir3dl1 were 
determined relative to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
reference gene by real-time PCR, using Qiagen QuantiTect primer assays.  
 In the chronic hypoxic model, male C57/Bl6 mice, aged 11 weeks (Charles 
River), were randomized and placed in either hypoxic (10% O2) or normoxic (21% O2) 
conditions. On day 21, RVSP was measured by direct cardiac puncture, as previously 
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described3. Blood and tissues were collected and RV hypertrophy was assessed as 
detailed above for rats.  
Assessment of rat NK cell number and function 
For enumeration of NK cells in the blood and splenocytes, samples were treated with BD 
Pharm Lyse (BD Biosciences) to eliminate red blood cells and analyzed by flow 
cytometry following staining with PE-conjugated α-CD3 (clone 1F4) and APC-
conjugated α-NKR-P1A (clone 10/78, both Biolegend, San Diego, CA). Untouched 
splenic NK cells were magnetically isolated from splenocyte suspensions by negative 
selection using the method described by Poli and colleagues4, resulting in a yield that was 
>98% NKR-P1A+/CD3- NK cells (data not shown). Following isolation, assessment of 
NK cell activity was determined by as a measure of chromium release following a 6 hour 
incubation with 51Cr-loaded YAC-1 murine lymphoma target cells at the specified 
effector to target ratios.  
Assessment of mouse NK cell number and function 
Spleens were homogenized and filtered through a 40 µm cell strainer to yield single-cell 
suspensions. For enumeration of NK cells in the blood and spleen, lymphocytes were 
treated with BD Pharm Lyse cells and analyzed by flow cytometry following staining 
with FITC-conjugated α-CD45 (clone 30-F11), PE-conjugated α-CD3 (clone 17A2) and 
APC-conjugated α-NK1.1 (clone PK136, all BD Biosciences). For lung NK cell 
enumeration, fresh lung tissue was minced into 1mm3 segments and digested in PBS 
(with Ca2+ and Mg2+) containing 1 mg/mL collagenase type IV, 0.1 mg/mL DNase I 
(both from Sigma) and 2% FBS at 37°C for 1 hour under gentle agitation.  Following 
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digestion, cell suspensions were filtered through a 40 µm cell strainer and stained with 
the antibodies listed above. 
For assessment of murine NK cell function, PBMCs were isolated from 
splenocyte suspensions using Ficoll Paque Plus density gradient centrifugation and NK 
cells were enriched using the mouse NK cell isolation kit from Miltenyi Biotec. Ficoll 
centrifugation is necessary in this protocol to control for an altered hematocrit in hypoxic 
mice. The CD107a mobilization assay was conducted as described for human cells, with 
the following changes. NK cells were incubated with YAC-1 target cells in the presence 
of 1µL FITC-conjugated α-CD107a (clone 1D4B) and 50 µM β-mercaptoethanol. 
Following a 5-hour co-culture, cells were counterstained with α-CD3 and α-NK1.1, fixed 
and permeabilized using the fix-perm kit from BD Biosciences and stained for 
intracellular IFNγ using PE-Cy-7-conjugated α-IFNγ antibody (clone XMG1.2, BD 
Biosciences). In order to obtain a robust measure of IFNγ production, murine NK cells 
were also cultured with or without 10 ng/mL recombinant murine IL-12 (R&D systems), 
in complete RPMI, containing 1.4 µg/mL monensin and 50 µM β-mercaptoethanol. 
Following 4-hour cultures, cells were stained for surface markers and intracellular IFNγ 
as described above. 
Immunofluorescence 
Sections of fixed mouse lung tissue (6 µm) were labeled with polyclonal rabbit-α-mouse 
von Willebrand factor (Dako, Glostrup, Denmark), followed by NL637-conjugated 
donkey-α-rabbit IgG secondary antibody (R&D Systems), Cy3-conjugated mouse-α-rat 
smooth muscle α-actin (clone 1A4, Sigma) and nuclear staining with DAPI. Vessels with 
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diameters ranging from 25 to 75 µm were counted from 4 randomly chosen fields and 
categorized as either fully-, partially- or non-muscularized. 
MMP zymography and gene expression 
Cell culture supernatants and RNA were collected from 24-hour NK cell cultures as 
described above. For zymography, 10µL of supernatant was loaded onto a 10% 
polyacrylamide gel containing 2mg/mL gelatin. Following electrophoretic separation, 
gels were washed three times with 2.5% Triton-X100 for 20 minutes, followed by two 20 
minute washes with matrix metalloproteinase (MMP) digestion buffer (50 mM Tris-HCl, 
pH 7.6, 150 mM NaCl and 5 mM CaCl2).  Gels were then incubated for 16 hours in fresh 
digestion buffer prior to staining with 0.4% Coomassie blue R250 in 45% methanol and 
10% acetic acid.  Gels were destained with 30% methanol and 10% acetic acid prior to 
visualization. Gene expression of MMPs -2 and -9, tissue inhibitors of MMPs (TIMPs) -
1, -2 and -3, and extracellular matrix metalloproteinase inducer (EMMPRIN) were 
determined relative to HPRT1 by real-time PCR, using Qiagen QuantiTect primer assays. 
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Supplemental Table I: Subjects for Whole Blood Flow Cytometry
Subject ID Age Sex mPAP CI PVR Treatmenta PAH Classification BMPR2 Mutation
PAH Patients
P1 26 M 81 2.44 21.48 PGI idiopathic
P2 45 M 38 1.8 7.57 ERA heritable yes
P3 43 F 49 2.14 12.88 ERA idiopathic
P4 46 F 54 3.71 7.13 ERA idiopathic
P5 29 F 51 2.1 15.2 PDEI heritable yes
P6 41 F 58 2.1 11.1 ERA idiopathic
P7 50 F 45 3.21 6.59 PDEI idiopathic
P8 65 F 42 1.58 12.23 ERA idiopathic
P9 50 F 44 1.24 14.85 PGI idiopathic
P10 52 F 56 1.78 15.6 PGI idiopathic
P11 31 M 60 2.7 10.82 PGI heritable
Summary 42.8 +/- 3.4 73% female 52.5 +/- 3.5 2.3 +/- 0.2 12.3 +/- 1.3
CTEPH Patients
C1 32 M 40 1.83 5.95 naïve
C2 74 M 38 2.37 6.41 naïve
C3 44 F 50 1.71 12.65 naïve
C4 64 M 60 2.27 10.91 naïve
C5 46 F 50 2.18 8.84 naïve
C6 67 F 47 1.57 15.35 naïve
C7 67 F 54 1.64 18.07 naïve
C8 42 M 52 2.25 11.87 naïve
C9 73 F 49 1.93 7.26 naïve
Summary 56.6 +/- 5.2 56% female 48.9 +/- 2.2 2.0 +/- 0.1 10.8 +/- 1.4
Healthy Donors 
Summary 39.8 +/- 1.7 68% female
(n=37)
a. Treatment class abbreviations: ERA - Endothelin Receptor Antagonists, PGI - Prostacyclin Analogues, 
PDEI - Phosphodiesterase Inhibitors
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Supplemental Table II: Subjects for Isolated NK Cell Experiments
Subject ID Age Sex Ethnicity mPAP CI PVR 6 min walk Treatmenta PAH Classification BMPR-II Mutation
PAH Patients
P12b 41 F Caucasian 62 n/a n/a 385 ERA, PGI idiopathic yes
P13b 40 F Asian 70 4.1 9.66 507 ERA, Gleevec idiopathic
P4 48 F Caucasian 54 4 6.5 562 ERA idiopathic
P14 35 F Caucasian 65 1.9 n/a 459 ERA, PDEI heritable yes
P15 37 M Caucasian 97 1.9 20.99 550 PGI, PDEI idiopathic
P16 62 F Caucasian 72 1.6 n/a 337 ERA, PDEI idiopathic
P17 33 M Caucasian 54 1.6 15 439 PGI, PDEI idiopathic
P18 45 F Caucasian n/a n/a n/a 388 ERA, PGI idiopathic
P19 77 M Caucasian 58 3.5 13.2 270 ERA, PGI idiopathic
P11 32 M Caucasian 60 2.69 10.8 400 PGI, PDEI heritable
P20 36 F Oriental 40 1.36 19.6 482 ERA, PGI idiopathic yes
P21c 45 M Caucasian 46 1.75 9.7 381 ERA, PDEI heritable yes
P22c 49 F Caucasian 38 2.8 7.76 368 PGI idiopathic
P23c 56 F Caucasian 54 2.38 10.43 473 PDEI idiopathic
Summary 45.4 +/- 3.4 64% female 59.2 +/- 4.1 2.5 +/- 0.3 12.4 +/- 1.5 428 +/- 22
Healthy Donors
H1b 37 F Caucasian
H2 45 F Asian
H3 50 F Caucasian
H4 35 F Caucasian
H5 40 M Caucasian
H6 58 F Caucasian
H7 30 M Caucasian
H8 45 F Caucasian
H9 55 M Caucasian
H10 47 M Caucasian
H11 28 F Oriental
H12c 53 M Caucasian
H13c 54 F Caucasian
H14c 59 F Caucasian
H15c 51 F Caucasian
Summary 45.8 +/- 2.6 67% female
a. Treatment class abbreviations: ERA - Endothelin Receptor Antagonists, PGI - Prostacyclin Analogues, PDEI - Phosphodiesterase Inhibitors
b. Donors only used for phenotypic characterization of NK cells and not subsequent functional or mechanistic 
studies.  One patient transplanted, one relocated. One healthy donor relocated.
c. Donors not characterized for surface expression of activating receptors or KIR2DL1/S1 due to changes in cytometer and antibody availability.
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Supplemental Table III: Primers for KIR and HLA Genotyping
Target Sense Primers (sequence 5'-3') Antisense Primers (sequence 5'-3')
KIR3DL1 (all alleles) CCTGGTGAAATCAGGAGAGAG 1.8 TAGGTCCCTGCAAGGGCAA 1.8 182
KIR3DS1 (all alleles) CCTGGTGAAATCAGGAGAGAG 2.4 CAAGGGCACGCATCATGGA 2.4 173
HLA-Bw4 GCGAGGGGACCGCAGGC 2 CGCTCTGGTTGTAGTAGCG 2 395
TCGCTCTGGTTGTAGTCGC 2 396
CGCTCTGGTTGTAGTAGGG 2 395
HLABw6 GCGAGGGGACCGCAGGC 2 CGCTCTGGTTGTAGTAGCC 2 395
HLA-Bw480T GCGAGGGGACCGCAGGC 2 TTGTAGTAGCGGAGCAGGG 2 387
TGTAGTAGCGGAGCGCGG 2 386
TGTAGTAGCGGAGCGGGG 2 386
HLA-Bw480I TACCGAGAGAACCTGCGGAT 2 TGGGTGATCTGAGCCGCG 2 454
GGGTGATCTGAGCCGCCG 2 453
HLA-Cw2 CCGCGAGTCCGAGAGGG 2 CGCGCAGTTTCCGCAGGT 2 129
GCCGCGAGTCCAAGAGG 2 130
HLA-Cw1 CCGCGAGTCCGAGAGGG 2 GCGCAGGTTCCGCAGGC 2 128
GCCGCGAGTCCAAGAGG 2 129
Control Primers (added to each primer mix to verify successful DNA amplification)
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Supplemental Figure 3. Assessment of EMMPRIN and TIMP gene expression in 
isolated NK cells. Gene expression of (A) EMMPRIN and (B-D) TIMPs -1, -2 and -3 in 
isolated NK cells after 24 hours of ex vivo culture. Quantification of active (D) MMP-2 
and (E) MMP-9 secretion by densitometry. n=9-12, * P<0.05. 
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